Scientists performed a systematic high-throughput combination drug screen and identified a synergistic interaction between the MEK inhibitor trametinib and the multi-kinase inhibitor nintedanib, which targeted KRAS-directed oncogenic signaling in mesenchymal PDAC.
[Nature Cancer]
7992332
{7992332:AAAAAAAA}
apa
50
1
171349
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
